Rockwell Medical, Inc. operates as an integrated biopharmaceutical company in the United States and internationally. The company offers products and services for the treatment of end-stage renal disease, chronic kidney disease (CKD), iron deficiency, secondary hyperparathyroidism, and hemodialysis (HD). Its products are used to cleanse patients' blood and replace nutrients lost during the kidney dialysis process. The company manufactures, sells, delivers, and distributes HD concentrates, such as CitraPure citric-acid concentrate, Dri-Sate dry acid, Renal Pure liquid acid concentrate, dry acid concentrate mixing system, RenalPure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. It also intends to offer Calcitriol, a generic active vitamin D for the treatment of secondary hyperparathyroidism in dialysis patients. In addition, the company is also developing Soluble Ferric Pyrophosphate, which is in two Phase III clinical trials for iron therapy treatment in CKD-HD patients. Rockwell Medical, Inc. sells its products directly to hemodialysis providers, as well as through independent sales agents and distributors. The company was founded in 1995 and is based in Wixom, Michigan.